Cogent Biosciences Inc | - | 8.58% | - | - | 215,125 |
| WVE | 6.31% | 15.950 | -6.18% | 344,186 | |
| LIVN | 6.10% | 60.64 | -1.45% | 96,285 | |
Travere Therapeutics Inc Ordinary Shares | - | 5.80% | - | - | 143,453 |
Guardant Health Inc | - | 4.79% | - | - | 46,614 |
Corcept Therapeutics Inc | - | 4.75% | - | - | 56,594 |
TransMedics Group Inc | - | 4.27% | - | - | 33,455 |
BridgeBio Pharma Inc | - | 4.11% | - | - | 53,501 |
Savara Inc | - | 3.98% | - | - | 619,284 |
Mirum Pharmaceuticals Inc | - | 3.93% | - | - | 48,433 |
The RBB Fund, Inc. - F/m Emerald Life Sciences Innovation ETF is an exchange traded fund launched by The RBB Fund, Inc. The fund is managed by Emerald Mutual Fund Advisers Trust and F/M Investments LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating across health care, health care equipment and services, health care providers and services, health care distributors, pharmaceutical product distribution, health care services, healthcare provider support persons, home healthcare services, pharmaceuticals, biotechnology and life sciences, life sciences tools and services, pharmaceuticals products, pharmaceuticals research and development, medical diagnostics, medical devices, healthcare technologies and synthetic biology sectors. It invests growth and value stocks of companies across diversified market capitalization. The fund employs proprietary research to create its portfolio. The RBB Fund, Inc. - F/m Emerald Life Sciences Innovation ETF was formed on October 30, 2024, and is domiciled in the United States.